Mergers & AcquisitionsBy The Online Investor Staff, updated Thu., Mar. 4, 2:01 PM
|This Slide: #8 of 100|
Slide #8. Bio-Techne Corporation — Asuragen, Inc.
Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Asuragen, Inc. for initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. The transaction will be financed through a combination of cash on hand and an existing revolving line of credit. Bio-Techne anticipates the acquisition to close in the fourth quarter of its fiscal 2021.
Bio-Techne and its subsidiaries develop, manufacture and sell life science reagents, instruments and services for the research and clinical diagnostic markets.Co.'s segments include: Protein Sciences, which developes and manufactures purified proteins and reagent solutions, cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies; and Diagnostics and Genomics, which develops and manufactures diagnostic products, including Food and Drug Administration-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for Original Equipment Manufacturer.
TECH SEC Filing Email Alerts Service
Open the TECH Page at The Online Investor »
Buy (3.33 out of 4)